<DOC>
	<DOCNO>NCT00018941</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell . It yet know regimen interleukin-2 effective kidney cancer . PURPOSE : Randomized phase III trial compare effectiveness different regimen interleukin-2 treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate overall survival patient metastatic renal cell carcinoma treat either low-dose high-dose intravenous interleukin-2 ( IL-2 ) subcutaneous IL-2 . II . Compare toxic effect 3 regimen patient population . OUTLINE : This randomize study . Patients stratify accord presence renal tumor ( yes v ) . Patients randomize one three treatment arm . Arm I : Patients receive low dose interleukin-2 ( IL-2 ) IV every 8 hour 15 dos . Treatment repeats 7-10 day one complete course . Arm II : Patients receive high dose IL-2 IV every 8 hour 15 dos . Treatment repeats 7-10 day one complete course . Arm III : Patients receive IL-2 subcutaneously daily 5 day week 6 week . Treatment continue absence disease progression unacceptable toxicity . Patients stable respond disease receive additional complete course therapy . PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , metastatic renal cell carcinoma measurable disease No 25 % liver replace tumor No CNS involvement major nerve compression allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : Not specify Hepatic : Bilirubin le 2.0 mg/dL AST ALT great 3 time normal Renal : Creatinine le 1.6 mg/dL Cardiovascular : Normal EKG Normal thallium stress test ( require patient 50 year age old clinically indicate ) Pulmonary : FEV1 VC great 65 % predict ( pulmonary function screening require patient significant smoke history suspicion pulmonary disease ) Other : No second malignancy , except : Basal cell skin cancer Carcinoma situ cervix No significant psychiatric disease would preclude consent treatment No systemic infection No coagulation disorder bleed Not pregnant HIV negative PRIOR CONCURRENT THERAPY : No prior therapy within 28 day Biologic therapy : No prior interleukin2 Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>